| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8723458 | Médecine des Maladies Métaboliques | 2017 | 4 Pages |
Abstract
Aside from the therapies that have targeted the treatment of NonAlcoholic SteatoHepatitis (NASH) with antidiabetic agents (pioglitazone, GLP-1 receptor agonists), research is now focusing on specific therapies that we discuss in this short review. The difficulties of evaluating the effects, given the diversity of the stages of the disease, and the need to rely on robust judgment criteria, are also mentioned.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
L. Serfaty,